News

AGROSPHERES ANNOUNCES NOVEL MODALITIES PARTNERSHIP WITH BAYER

AgroSpheres’ AgriCell technology will help deliver the next generation of high-performing, environmentally safe crop protection

CHARLOTTESVILLE, VA – AgroSpheres, INC., a leader in developing the next generation of environmentally friendly crop protection products, today announced a multi-year collaboration with Bayer to create novel modalities of biologicals for use as crop protection products.

“Teaming up with a leading global partner like Bayer helps us execute a mission we are both passionate about – transforming agriculture with better and more sustainable products for growers,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “This collaboration also brings us one step closer to establishing AgroSpheres as a next-generation biosciences company.”

AgroSpheres’ patented AgriCell manufacturing technology enables the production of encapsulated biomolecules with enhanced stability, field persistence and targeted delivery.

“AgroSpheres’ novel AgriCell systems are innovative technologies that will help us to explore new sustainable crop protection products,” said Rachel Rama, Head of Small Molecules for Bayer. “AgroSpheres’ cutting-edge scientific team will help us as we continue to improve innovative product offerings for our grower customers.”

Biomolecules such as peptides and nucleic acids have demonstrated great promise in the lab but have generally struggled to yield consistent results for commercial biological development. The AgriCell technology fills the missing link in delivering reliable field performance and opening new markets for high-performance biopesticides. Used with novel modalities, AgriCell technology will help deliver biopesticides that:

  • Outperform traditional biologicals
  • Are non-toxic to humans and animals
  • Are durable in the environment
  • Target specific pests
  • Help manage resistance

Read more here.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients